{Reference Type}: Case Reports
{Title}: Plasma Concentrations of Tranylcypromine in Depressed Patients With Chronic Kidney Disease: Two Case Reports.
{Author}: Först C;Ulrich S;Zurek G;Seifert S;Frank M;Scheidel B;
{Journal}: J Clin Psychopharmacol
{Volume}: 44
{Issue}: 3
{Year}: 2024 May-Jun 1
{Factor}: 3.118
{DOI}: 10.1097/JCP.0000000000001866
{Abstract}: <B>OBJECTIVE: </B>The prevalence of comorbid depression and chronic kidney disease (CKD) is high. The aim of this brief report was to review 2 cases of treatment with tranylcypromine (TCP) in patients with treatment-resistant depression (TRD) and CKD. Tests of the plasma concentration of TCP were included.<BR><B>METHODS: </B>Medical and psychiatric notes of the 2 patients were reviewed with plasma concentrations of TCP as a key aspect of the discussion. The data are evaluated in the context of relevant medical and pharmacokinetic literature.<BR><B>RESULTS: </B>Plasma concentrations of TCP are highly variable both in patients with and without CKD. Plasma concentrations of TCP were not increased in the 2 cases with CKD as compared with literature data of patients without CKD. No signs of intoxication were detected in 2 cases with CKD that impaired continuous treatment of depression with TCP.<BR><B>CONCLUSIONS: </B>TCP may be considered in selected cases of TRD with concomitant CKD. More clinical data and tests of plasma concentrations of TCP are needed in patients with CKD.